Efficacy, safety and 10-year cardiovascular disease risk reduction of alirocumab and evolocumab therapy in addition to maximal tolerated cholesterol lowering therapy in patients with hypercholesterolemia and cardiovascular disease
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 New trial record